Abstract： The implementation of “The Belt and Road” Initiative has given some opportunities and challenges for Chinese pharmaceutical import and export. This paper expounds the effects of “The Belt and Road” Initiative on Chinese pharmaceutical industry, analyzes the situations of import and export between China and the countries along “The Belt and Road” after the initiative was launched respectively from Northeast Asia, Southeast Asia, South Asia, West Asia and North Africa, Central and Eastern Europe, Central Asia and other six countries in the Commonwealth of the Independent States, and finds the existing shortages of Chinese pharmaceutical foreign trade such as the low degree of industry concentration, the little difference on products, the insufficient innovation ability, and proposes some suggestions, such as developing the large pharmaceutical market along “The Belt and Road”, exploring the pharmaceutical market demand along “The Belt and Road”, improving the level of independent innovation technology, and studying the market access policy of the main countries along “The Belt and Road”, which will play a positive role in the further deepening of “The Belt and Road” Initiative in pharmaceutical industry.
潘琪1,2 王隽3 徐晓媛1 郭梦佳2. “一带一路”背景下我国医药产品进出口现状与发展[J]. 中国医药导报, 2019, 16(5): 168-171.
PAN Qi1,2 WANG Juan3 XU Xiaoyuan1 GUO Mengjia2. Current situation and development of import and export of Chinese pharmaceutical products under the background of “The Belt and Road”. 中国医药导报, 2019, 16(5): 168-171.
2019, Vol. 16 
京公网安备 11010502046598号